Karyopharm Therapeutics Inc.
KPTI Healthcare Biotechnology
Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.
Follow KPTI
Karyopharm Therapeutics Inc. (KPTI) P/E ratio
Karyopharm Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| KPTI Karyopharm Therapeutics Inc. | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)